DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML)

Olga Krali, Josefine Palle, Christofer L. Backlin, Jonas Abrahamsson, Ulrika Noren-Nyström, Henrik Hasle, Kirsi Jahnukainen, Olafur Gisli Jónsson, Randi Hovland, Birgitte Lausen, Rolf Larsson, Lars Palmqvist, Anna Staffas, Bernward Zeller, Jessica Nordlund

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Sammanfattning

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease composed of clinically relevant subtypes defined by recurrent cytogenetic aberrations. The majority of the aberrations used in risk grouping for treatment decisions are extensively studied, but still a large proportion of pediatric AML patients remain cytogenetically undefined and would therefore benefit from additional molecular investigation. As aberrant epigenetic regulation has been widely observed during leukemogenesis, we hypothesized that DNA methylation signatures could be used to predict molecular subtypes and identify signatures with prognostic impact in AML. To study genome-wide DNA methylation, we analyzed 123 diagnostic and 19 relapse AML samples on Illumina 450k DNA methylation arrays. We designed and validated DNA methylation-based classifiers for AML cytogenetic subtype, resulting in an overall test accuracy of 91%. Furthermore, we identified methylation signatures associated with outcome in t(8;21)/RUNX1-RUNX1T1, normal karyotype, and MLL/KMT2A-rearranged subgroups (p < 0.01). Overall, these results further underscore the clinical value of DNA methylation analysis in AML.

Originalspråkengelska
Artikelnummer895
TidskriftGenes
Volym12
Utgåva6
Antal sidor16
ISSN2073-4425
DOI
StatusPublicerad - 10 juni 2021
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3121 Allmänmedicin, inre medicin och annan klinisk medicin
  • 3123 Kvinno- och barnsjukdomar

Citera det här